biohack.The longevity wire
LIVE WIREUpdated · scanning every 6 hours
16:38 Statin users had about double the dementia risk in two big health studies✦16:35 Anthropic lays out plans for its Claude AI to help invent new drugs✦16:31 FDA clears a test of a brain-fluid drain in early Alzheimer's, maker says✦16:28 Lewy body dementia pill missed main trial goal; maker cites low drug levels✦16:26 Cell therapy from patients' own tumors shrank lung cancer in 1 in 4, maker says✦16:25 More daily steps tied to sharper attention in a 14-year Fitbit study✦16:22 One spinal shot lowered the Huntington's protein by about 60%, maker says✦10:27 Gut bacteria chemical tied to irregular heartbeat in people and mice✦16:38 Statin users had about double the dementia risk in two big health studies✦16:35 Anthropic lays out plans for its Claude AI to help invent new drugs✦16:31 FDA clears a test of a brain-fluid drain in early Alzheimer's, maker says✦16:28 Lewy body dementia pill missed main trial goal; maker cites low drug levels✦16:26 Cell therapy from patients' own tumors shrank lung cancer in 1 in 4, maker says✦16:25 More daily steps tied to sharper attention in a 14-year Fitbit study✦16:22 One spinal shot lowered the Huntington's protein by about 60%, maker says✦10:27 Gut bacteria chemical tied to irregular heartbeat in people and mice
← All story threadsSTORY THREAD

CervoMed's pill for dementia with Lewy bodies.

1 report so far. New developments are added to this thread as they happen.

  1. Oct 29, 2026
    CONTROLLED TRIAL RESULTS PUBLISHED IN A JOURNALControlled trial · 159 people

    Lewy body dementia pill missed main trial goal; maker cites low drug levels

    A journal has published the placebo-controlled results of CervoMed's 159-person trial of neflamapimod. The pill did not beat placebo overall, and the company points to capsules that delivered too little drug.